Wireless Pressure Sensor Assisted Orthopedic Nursing Effectiveness Evaluation

This paper combines flexible pressure sensing technology, wireless sensor network, and cloud platform technology to design and manufacture a medical miniature pressure sensor and its supporting system. The problem of noninvasive monitoring of the syndrome encountered in the clinic is used for real-time monitoring and auxiliary diagnosis of the disease. Different from the current clinical use of “puncture” to measure intrafascial pressure, this system focuses on the noninvasive monitoring of compartment syndrome, using medical tape to paste a flexible microsensing unit on the injured area. The flexible sensor unit can measure the pressure here in real time and then can know the pressure in the fascia chamber. The flexible pressure sensor unit combines with the subsequent flexible circuit to send the measured data to the data in real time through wireless communication. The data aggregation node transmits the collected data to the upper computer through serial communication, and the upper computer software processes and stores the data and uploads it to the cloud server. In this experiment, it was observed that the concentrations of Ca and P showed the same fluctuating trend. With the gradual progress of the stretch, the concentrations of Ca and P increased with the increase in time, reaching approximately at the end of the extension. The peak value indicates that the osteoclast activity is enhanced at this time, the bone matrix is largely destroyed, and the Ca and P in the matrix are released into the serum in a large amount, thereby increasing the serum concentration. After the distraction ceases, it enters the healing period of the callus. At this time, the concentrations of Ca and P decrease with the increase in time and gradually reach a stable level, indicating that the osteoblast activity is enhanced at this time, the bone matrix begins to rebuild, and the Ca and P gradually increase. The deposited bone matrix gradually forms new bone and finally reaches a balance. Since the speed of extension in each experimental group is inconsistent, the time required to reach the same extension length is also inconsistent, so that the peak time is also inconsistent. After plotting the stress difference ( △ F ) before and after stretching against time and speed, it is found that the relationship is linear. However, these two variables affect △ F at the same time, so they cannot be isolated. Based on this, this subject uses multiple regression equations to fit the three relationships of stress difference ( △ F ), time, and speed. In the process of distraction osteogenesis, with each distraction, the bone stress presents a trend from high to low. And as the stretch progresses, the measured stress value increases linearly at the same time point every day.

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Utilizing the prespecified longitudinal systematic collection of plasma samples in the phase 1/2a LYM1002 trial (NCT02329847), we tested the clinical validity of ctDNA for baseline mutation profiling, residual tumor load quantification, and acquisition of resistance mutations in patients with lymphoma treated with ibrutinib plus nivolumab. Inclusion criterion for this ancillary biological study was the availability of blood collected at baseline and cycle 3 day 1. Overall, 172 ctDNA samples from 67 patients were analyzed using LyV4.0 ctDNA CAncer Personalized Profiling by deep Sequencing assay. Among baseline variants in ctDNA, only TP53 mutations (detected in 25.4% of patients) were associated with shorter progression-free survival; clones harboring baseline TP53 mutations did not disappear during treatment. Molecular response, defined as a >2-log reduction in ctDNA levels after 2 cycles of therapy (28 days), was achieved by 28.6% of patients with relapsed diffuse large B-cell lymphoma who had ≥1 baseline variant and was associated with best response and improved progression-free survival. Clonal evolution occurred frequently during treatment, and 10.3% new mutations were identified after 2 treatment cycles in nonresponders. PLCG2 was the topmost among genes that acquired new mutations. No patients acquired C481S BTK mutations implicated in resistance to ibrutinib in CLL. Collectively, our results provide the proof of concept that ctDNA is useful for noninvasive monitoring of lymphoma treated with targeted agents in the clinical trial setting.